Clinical trials: Early Stage Non-small Cell Lung Cancer
Anorexia, Cachexia
Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer
RATIONALE: Megestrol helps improve appetite. It is not yet known if megestrol is effective in limiting weight loss in patients who are undergoing radiation therapy.
- Conditions
- Anorexia, Cachexia, Lung Cancer
- Trial name
- NCT00031785
- Testing
- megestrol acetate, radiation therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Wake Forest University Health Sciences
NSCLC, Stage I, NSCLC, Stage II
A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China
This study is a prospective, national, multi-center, non-interventional study. The main purpose is to explore the initial adjuvant treatment pattern after radical resection for early-stage NSCLC patients with EGFR…
- Conditions
- NSCLC, Stage I, NSCLC, Stage II, NSCLC, Stage III
- Trial name
- ADDRESS (NCT04830826)
- Testing
- Surgeries
- Where
- 51 sites in China
- Volunteers
- 1,490 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Non Small Cell Lung Cancer
A Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China
Nivolumab (BMS-936558) is a fully human, IgG4 (kappa) isotype mAb that binds PD-1 on activated immune cells and disrupts engagement of the receptor with its ligands PD-L1 (B7 H1/CD274) and PD-L2 (B7-DC/CD273), thereby abrogating…
- Trial name
- NCT04015778
- Testing
- Nivolumab, carboplatin, nab-paclitaxel
- Where
- China
- Volunteers
- 316 people
- Sponsor
- Guangdong Association of Clinical Trials
Breast Cancer, Lung Cancer
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
RATIONALE: Gathering information about how often osteonecrosis of the jaw occurs in patients receiving zoledronic acid for bone metastases may help doctors learn more about the disease and provide the best follow-up care.
- Conditions
- Breast Cancer, Lung Cancer, Metastatic Cancer, Multiple Myeloma
- Trial name
- NCT00874211
- Testing
- assessment of therapy complications
- Where
- 453 sites in United States, Mexico and 1 more
- Volunteers
- 3,571 people
- Sponsor
- SWOG Cancer Research Network
Non-small Cell Lung Cancer
Daily vs. Non-Daily SBRT for NSCLC
The purpose of this study is to determine if stereotactic body radiotherapy (SBRT) on non-consecutive days will increase the chances of curing non-small cell lung cancer when compared to daily treatment.
- Trial name
- NCT03624907
- Testing
- Daily Stereotactic Body Radiotherapy, Non-Daily Stereotactic Body Radiotherapy
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Florida
Lung Cancer
Photodynamic Therapy With HPPH in Treating Patients With Non-Small Cell Lung Cancer
RATIONALE: Photodynamic therapy uses light and drugs that make tumor cells more sensitive to light to kill tumor cells. Photosensitizing drugs such as HPPH are absorbed by tumor cells and, when exposed to light, become active and…
- Trial name
- NCT00025571
- Testing
- HPPH
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Lung Cancer
Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as vinorelbine, cisplatin, docetaxel, gemcitabine, and pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT00863512
- Testing
- cisplatin, docetaxel, gemcitabine hydrochloride
- Where
- 94 sites in United States, Australia
- Volunteers
- 34 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Early Stage Lung Cancer (I and II), Non-Small Cell Lung Cancer
Multicenter Analysis of Different Approaches in Segmentectomies in Early-stage Lung Cancer
The study is a retrospective, observational and multicentric study. The study describes robotic segmentectomies performed in four referred centers, with the aim to assess the perioperative compilications of robotic…
- Trial name
- ANASEGME (NCT06737107)
- Where
- 4 sites in Italy
- Volunteers
- 472 people
- Sponsor
- Scientific Institute San Raffaele
Non Small Cell Lung Cancer
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
In Cohort 1, the study was intended to assess safety and efficacy of neoadjuvant combination of IPH5201 and durvalumab in addition to standard chemotherapy and adjuvant combination of IPH5201 and durvalumab, in untreated patients…
- Trial name
- NCT05742607
- Testing
- IPH5201 + durvalumab + standard chemotherapy
- Where
- 30 sites in United States, France and 3 more
- Volunteers
- 70 people
- Sponsor
- Innate Pharma
Primary Early-stage Non-small Cell Lung Cancer
TILs Therapy for Multiple Primary Early-Stage NSCLC
This is a single-arm study aimed at evaluating the safety of TILs therapy for multiple primary early-stage NSCLC
- Trial name
- NCT07498439
- Testing
- TILs injection
- Volunteers
- 50 people
- Sponsor
- Tianjin Medical University General Hospital
Carcinoma, Non-Small-Cell Lung
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
This study is a multicenter, prospective, cohort study designed to evaluate the clinical outcomes and characteristics of resected stage II-IIIB anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) adult…
- Trial name
- NCT06862869
- Testing
- Alectinib
- Where
- 44 sites in China
- Volunteers
- 800 people
- Sponsor
- Hoffmann-La Roche
Resectable, Early-stage
Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer
Study D9108C00002 (NeoCOAST) is a platform study assessing the effectiveness and safety of neoadjuvant durvalumab alone or in combination with novel agents in participants with resectable, early-stage (Stage I [>2cm] to IIIA)…
- Conditions
- Resectable, Early-stage, NSCLC
- Trial name
- NCT03794544
- Testing
- Durvalumab, Oleclumab, Monalizumab
- Where
- 18 sites in United States, Canada and 5 more
- Volunteers
- 84 people
- Sponsor
- MedImmune LLC
Advanced Non-small Cell Lung Cancer
Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Early Stereotactic Body Radiation Therapy to the Primary Tumor in Advanced Non-small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is a prevalent disease with high mortality and morbidity, particularly of adenocarcinoma in Asians.
- Trial name
- NCT03727867
- Testing
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Stereotactic Body Radiation Therapy
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Haihua Yang
Cancer, Non Small Cell Lung Cancer
Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients
This exploratory clinical study is designed to obtain pre-therapeutic imaging assessments using positron emission tomography (PET) imaging in 21 patients with Stage IIIB/IV or recurrent non-small cell lung cancer (NSCLC) and an…
- Trial name
- NCT00708448
- Testing
- PET Imaging, Erlotinib, Bevacizumab
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Utah
NSCLC, Stage I
Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for Surgery
This study aims to evaluate the safety and mechanisms of action of the trimodality treatment (radiotherapy, immunotherapy and surgery) in early-stage non-small cell lung cancer.
- Trial name
- NCT03446911
- Testing
- SABR, SABR + pembrolizumab
- Volunteers
- 20 people
- Sponsor
- Amsterdam UMC, location VUmc
Carcinoma, Non-Small-Cell Lung
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab with SoC SBRT versus placebo with SoC SBRT in patients with unresected clinical Stage I/II…
- Trial name
- PACIFIC-4 (NCT03833154)
- Testing
- Durvalumab, (Osimertinib cohort, single-arm, open-label separate cohort)
- Where
- 209 sites in United States, Australia and 18 more
- Volunteers
- 724 people
- Sponsor
- AstraZeneca
Lung Cancer
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT00750269
- Testing
- SBRT 40.0 Gy, SBRT 42.5 Gy, SBRT 45.0 Gy
- Where
- 58 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- Radiation Therapy Oncology Group
Lung Cancer
Biomarkers in Predicting Response in Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy
This research trial studies prognostic and predictive markers in patients with early stage non-small cell lung cancer receiving chemotherapy.
- Trial name
- NCT01294280
- Testing
- Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 241 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non-small Cell Lung Cancer
Utility of Routine Cervical Mediastinoscopy in Clinical Stage I Non-Small Cell Lung Cancer (NSCLC)
To prospectively look at the utility of routine cervical mediastinoscopy (lymph node biopsy) in patients with clinically staged T2N0M0 NSCLC, as well as patients with clinically staged T1N0M0 NSCLC with a high maxSUV of the…
- Trial name
- NCT01146366
- Where
- 4 sites in United States
- Volunteers
- 111 people
- Sponsor
- Jennifer Bell
Non Small Cell Lung Cancer
Feasibility Study of the Aliya System in the Treatment of Early Stage Non-small Cell Lung Cancer
A prospective, two-arm, non-randomized, concurrently controlled, multi-center, open-label, treat and resect study following patients to 1 year.
- Trial name
- INCITE ES (NCT04732520)
- Testing
- Pulsed electric field treatment using the Aliya System
- Where
- 4 sites in Hong Kong, Netherlands and 1 more
- Volunteers
- 47 people
- Sponsor
- Galvanize Therapeutics, Inc.